Ruxolitinib, a JAK1/2 inhibitor, has shown therapeutic potential in HLH by targeting key immune cells involved in hyperinflammation, including macrophages, NK cells, and T cells. This evidence concerns the gene JAK1 and hemophagocytic syndrome.